Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOC 1020 in Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT05747924Phase 2Completed
- Sponsor
- Avidity Biosciences
- Start
- Apr 2023
- Primary completion
- Mar 2026
- Modality
- Antisense DNA, Antibody-Drug Conjugates (ADCs), Conjugated siRNA
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of delpacibart braxlosiran in facioscapulohumeral muscular dystrophy (FSHD) (5 arms), sponsored by Avidity Biosciences. Primary endpoints: Incidence of treatment-emergent adverse events at Day 365 and Change in plasma KHDC1L at Month 12. Started Apr 2023; status: completed.
02
Drugs
delpacibart braxlosiran
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT05747924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747924.